as 11-12-2024 2:33pm EST
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | SCOTTSDALE |
Market Cap: | 124.4M | IPO Year: | 2021 |
Target Price: | $9.50 | AVG Volume (30 days): | 158.9K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.04 | EPS Growth: | N/A |
52 Week Low/High: | $2.85 - $8.11 | Next Earning Date: | 11-19-2024 |
Revenue: | $77,681,000 | Revenue Growth: | 26.38% |
Revenue Growth (this year): | -26.44% | Revenue Growth (next year): | 50.57% |
DERM Breaking Stock News: Dive into DERM Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
7 days ago
MT Newswires
8 days ago
Zacks
8 days ago
GlobeNewswire
8 days ago
GlobeNewswire
18 days ago
ACCESSWIRE
a month ago
GlobeNewswire
a month ago
Simply Wall St.
a month ago
The information presented on this page, "DERM Journey Medical Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.